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Abstract: Salivary proteins such as histatins (HTNs) have demonstrated critical biological functions
directly related to tooth homeostasis and prevention of dental caries. However, HTNs are susceptible
to the high proteolytic activities in the oral environment. Therefore, pH-sensitive chitosan nanoparticles (CNs) have been proposed as potential carriers to protect proteins from enzymatic degradation
at physiological salivary pH. Four different types of chitosan polymers were investigated and the
optimal formulation had good batch to batch reproducibility, with an average hydrodynamic diameter of 144 ± 6 nm, a polydispersity index of 0.15 ± 0.04, and a zeta potential of 18 ± 4 mV at a final
pH of 6.3. HTN3 encapsulation and release profiles were characterized by cationic polyacrylamide
gel electrophoresis. The CNs successfully encapsulated HTN3 and selectively swelled at acidic pH
to facilitate HTN3 release. Protection of HTN3 against enzymatic degradation was investigated in
diluted whole saliva. HTN3 encapsulated in the CNs had a prolonged survival time compared to
the free HTN3. CNs with and without HTN3 also successfully reduced biofilm weight and bacterial
viability. The results of this study have demonstrated the suitability of CNs as potential protein
carriers for oral applications, especially for complications occurring at acidic conditions.
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1. Introduction
Saliva is a complex fluid composed of proteins, enzymes, and a variety of electrolytes.
Many physiological functions, such as chewing, digestion, wetting, and lubrication are
regulated by saliva [1]. The concentration of proteins present in the saliva may be used to
monitor oral health, as the severity and occurrence of oral diseases have been associated
with the composition and quantitative changes in salivary proteins [2]. Many of the salivary
proteins are active in the regulation of tooth homeostasis, either by directly exerting
antimicrobial effects or interfering with microbial colonization [3]. Examples include
statherin, histatins (HTNs), defensins, lactoferrin, and mucin [4]. In particular, the HTNs
are of great interest because these proteins are multifunctional. They have demonstrated
biological functions including the inhibition of calcium and phosphate precipitation on
enamel and antimicrobial activities, which are directly related to the regulation of oral
homeostasis [5–7]. The HTNs mainly consist of HTN1, HTN3, and HTN5, and each supplies
about 20–30% of the total HTN pool [8]. HTN1 is the only phosphorylated HTN able to
reduce bacterial colonization on tooth surfaces [9]. HTN5 has the most potent antifungal
activity against the pathogenic yeast Candida albicans [10]. HTN3 was demonstrated to
be the most effective in killing against Streptococcus mutans (S. mutans) [11], which is a
significant contributor towards dental caries.
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These proteins are often present in low concentrations inside the oral cavity due to
the high proteolytic activity of saliva [12,13]. Therefore, we proposed a delivery system to
encapsulate and protect these proteins for their use as inhibitors of tooth decay. The use
of stimulus-responsive polymeric nanoparticles synthesized from natural polymers has
recently gained substantial attention, as such smart delivery systems have the potential
to improve the overall colloidal stability of the encapsulated molecules and modulate
pharmacokinetics, often resulting in reduced toxicity and enhanced efficacy [14–17]. The
encapsulated cargo can be released in a stimulus-responsive manner. Examples of stimuli
include changes in pH, ionic strength, temperature, UV light, magnetic field, or the presence
of specific biological molecules [18–21]. In particular, for delivering drugs to the oral cavity,
it would be ideal for the delivery system to remain stable at physiological salivary pH
and selectively release the encapsulated cargo under acidic conditions. The pH-responsive
property is crucial because the oral environment acidifies following carbohydrate intake
as a result of the consumption of food and beverages. These conditions promote the
development of oral diseases such as dental caries and dental erosion [22,23].
Many polymer-based materials have been studied for applications in controlled drug
delivery, including naturally occurring biopolymers. For instance, chitosan is a copolymer
composed of N-acetyl-D-glucosamine and β(1–4) linked D-glucosamine [24]. It is mainly
obtained through the deacetylation of chitin under alkaline chemicals [25]. Chitin is a
biopolymer found in the exoskeletons of crustaceans, insects, and some fungi [26]. As
the only known naturally occurring polycationic polysaccharide and with its ability to
interact with anionic molecules, chitosan and its derivatives have been studied extensively
for applications in the agricultural, medicinal, and pharmaceutical industries [27–29].
Previous studies have utilized chitosan in toothpaste as an antimicrobial agent due to
its broad antimicrobial spectrum, covering both Gram-negative and Gram-positive bacteria
and fungi [30,31]. Aside from its antimicrobial effect, chitosan also offers other advantages
including biodegradability [32] and biocompatibility [33]. It also exhibits pH-dependent
solubility due to the presence of amino groups on the polymer chains [34]. The functional
amino groups can serve as platforms for interactions with other anionic molecules, where
the choice of anionic molecules depends on the intended applications.
Chitosan nanoparticles (CNs) have been commonly used to deliver therapeutic agents,
such as insulin [35], tretinoin [36], and doxorubicin [37]. In the current work, to the best
of our knowledge, for the first time we propose pH-sensitive chitosan nanoparticles for
salivary protein delivery. We hypothesize that salivary protein-loaded CNs can selectively
release the encapsulated proteins under low pH environments, offer protection against
proteolysis at the physiological salivary pH, and reduce S. mutans biofilm formation
on hydroxyapatite. To test these hypotheses, HTN3 was selected as the target protein,
and our objectives were to: (1) optimize CN formulation via ionic gelation with four
different types of chitosan polymers; (2) characterize both blank and HTN3-loaded CNs;
(3) quantify encapsulation and release profiles of HTN3; (4) assess the protection offered
by encapsulation against enzymatic degradation in human saliva; and (5) evaluate the
effectiveness of HTN3-loaded CNs in reducing S. mutans biofilm formation.
2. Materials and Methods
2.1. Materials
Ultra-low molecular weight (MW) chitosan (20 kg/mol, 91% deacetylated) and low
MW chitosan (1) (250 kg/mol, 91% deacetylated) were purchased from Glentham Life
Sciences (Corsham, UK). The other low MW chitosan (2) (50–190 kg/mol, 75–85% deacetylated), medium MW chitosan (190–310 kg/mol, 75–85% deacetylated), and ZipTip C18
pipette tips were acquired from Millipore Sigma (Oakville, ON, Canada). All filters, including 0.45 and 0.22 µm syringe filters and 10k Nanosep filters were purchased from
Pall Corporation (Mississauga, ON, Canada). HTN3 was acquired from Synpeptide Co.,
Ltd. (Shanghai, China). S. mutans UA159 was kindly donated by Dr. Yoav Finer from
the University of Toronto (Toronto, ON, Canada). Ceramic hydroxyapatite discs with
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5 mm diameter and 2 mm thickness were obtained from Clarkson Chromatography Products Inc. (South Williamsport, PA, USA). Bicinchoninic acid assay kit was acquired from
Thermo Fisher Scientific (Mississauga, ON, Canada). All other chemicals, including sodium
tripolyphosphate (TPP), were purchased from Millipore Sigma (Oakville, ON, Canada).
2.2. Optimized CNs Preparation
The ionic gelation procedure described previously was modified to optimize CNs
synthesis [38]. Briefly, preliminary experiments were done to assess the effect of chitosan
molar mass and degree of deacetylation, pH of chitosan/TPP solutions, and chitosan to TPP
mass ratios on CN characteristics. These particle preparations were performed in triplicate.
After determining the optimal conditions, unloaded CNs were synthesized by dissolving
100 mg of ultra-low MW chitosan in 100 mL of 0.4% v/v concentrated HCl. The pH of
the chitosan solution was adjusted to 5.9 and the solution was filtered through a 0.45 µm
syringe filter. Then, 100 mg of TPP was dissolved in 100 mL of Milli-Q water, its pH was
adjusted to 6.0 and solution was filtered through a 0.22 µm syringe filter. Finally, 0.36 mL of
TPP solution was added dropwise into 2.5 mL of chitosan solution under constant stirring
at 700 rpm, such that the mass ratio of chitosan to TPP was 6.94:1. HTN3-loaded CNs
were synthesized by mixing HTN3 with the chitosan solution before ionic gelation with
TPP. Briefly, 0.29 mL of the 0.1% w/v TPP solution was introduced dropwise into 2 mL of
0.1% w/v chitosan and 0.0025% w/v HTN3 under constant stirring at 700 rpm. The loading
ratio of chitosan to HTN3 by mass was 40:1, and 0.45 mL of the suspension contained 10 µg
of HTN3. The final pH of the nanoparticle solution was 6.3.
2.3. Characterizations of CNs
Unloaded CNs and HTN3-loaded CNs were initially characterized by measuring the
Z-average particle diameter, polydispersity index (PDI), and zeta potential by dynamic
light scattering (DLS, Malvern Zetasizer Nano ZS instrument, Malvern Instruments Ltd,
Malvern, UK) at a wavelength of 630 nm and a constant temperature of 25 ◦ C. To determine
the morphology of CNs, an aliquot from each CNs suspension was firstly desalted by dialyzing it against 1 L of deionized water for 3 h under constant stirring, using a 50 kg/mol
MW cut-off regenerated cellulose dialysis tubing (Spectrum Labs, New Brunswick, NJ,
USA). Then, samples were placed onto Formvar® -coated copper grid, dried overnight
under an air atmosphere, and the morphology of the CNs was visualized by transmission
electron microscopy (TEM, Philips CM10, Philips, Amsterdam, The Netherlands) at 80 kV.
To investigate the pH-dependence of CN size, initial (time = 0 min) particle size measurements were taken at a starting pH of 6.3. The pH of the suspension was then adjusted to 3.0,
4.0, or 5.0. After the pH adjustments, particle size, PDI, and zeta potential were assessed by
DLS at 10, 20, 30, 60, 120, and 240 min. To evaluate colloidal stability, CNs were stored at
4 ◦ C for 61 days. Particle size and zeta potential were measured by DLS on days 1, 10, 15,
22, 30, 35, 45, 52, and 61.
2.4. Encapsulation and Release of HTN3
To assess the pH-dependent release of HTN3 from HTN3-loaded CNs, 0.05 mL of
buffer (25 mM phosphate buffer/500 mM NaCl solution, pH 6.8), was added to 0.45 mL
of HTN3-loaded CNs suspension. The 0.5 mL of suspension was then filtered with a
10 kDa cut-off Nanosep filter by centrifuging the suspension at 14,000× g for 10 min to
separate free HTN3 (4063 Dalton) from the encapsulated CNs. The filtrate was collected to
determine encapsulation efficiency by cationic polyacrylamide gel electrophoresis (cationicPAGE) [39]. The pH of the retentate on top of the filter was adjusted to pH 3.0, 4.0, or 5.0
and incubated at 37 ◦ C for 30 min. The suspension was centrifuged again, allowing the
passage of released HTN3 through the filter. Subsequently, the filtrate was collected to
determine the extent of protein release by cationic-PAGE, using pure HTN3 as a reference
control. HTN3 encapsulation efficiency was tested for loading ratios of 2%, 5%, and 10%
w/w (HTN3 to chitosan). Encapsulation samples were prepared as previously described

Nanomaterials 2021, 11, 1028

4 of 15

with modifications to the mass ratio of HTN3 to chitosan. The encapsulation efficiency
was determined by Image Lab (BioRad) via the relative quantity tool, corresponding to the
ratio of the band volume and intensity divided by the reference (HTN3 standard) band
volume and intensity. To evaluate the cumulative release of HTN3, HTN3-loaded CNs were
prepared as previously described. Then, the retentate on top of the filter was incubated for
30, 60, 90, 120, 150, 180, and 210 min at 37 ◦ C in buffer solutions with different pH values
(6.8, 3.0, 4.0, or 5.0). Then, samples were centrifuged at 14,000× g for 10 min to separate
the released protein from the CNs. Subsequently, the filtrate was collected. This procedure
was repeated for each time point and the filtrate and a HTN3 standard were analyzed by
cationic-PAGE as previously described. The ability of the HTN3-loaded CNs to release
HTN3 under pH-cycling conditions, reflecting the pH changes that occur in the oral cavity,
was determined by incubating the CNs in buffer with pH of 6.8 and then in buffer with pH
4.0. This cycle was repeated for a total of four times, and the amount of HTN3 released
at each pH in function of time was determined by cationic-PAGE, following the protocol
previously described.
2.5. Protein Degradation Study
Considering that proteins are susceptible to proteolytic degradation inside the oral
cavity [40], the protection offered by encapsulation was evaluated in diluted whole saliva.
Stimulated whole saliva was collected by chewing a 5 cm × 5 cm parafilm piece from
three healthy individuals, between 9:00 am to 11:00 am, to minimize the effect of circadian
rhythm [13], and at least two hours after breakfast. Whole saliva was kept on ice during the
collection and then was immediately centrifuged for 10 min 14,000× g at 4 ◦ C to separate
the bacteria, cells, and other debris from the supernatant containing salivary proteins. The
concentration of salivary proteins in the supernatant, referred as whole saliva supernatant
(WSS), was quantified using a bicinchoninic acid assay kit. The degradation of free HTN3
was assessed in 10-fold diluted WSS, following the protocol previously reported [6]. Briefly,
50 µg of free HTN3 was added to diluted WSS (100 µg salivary protein/mL) in a final
volume of 1 mL. The pH was adjusted to 6.8 using 1 M HCl or 1 M NaOH, depending on
the pH of the WSS. Then, an aliquot of 100 µL was incubated for 0, 0.5, 1, 2, 3, or 6 h at
37 ◦ C. At each time point, samples were boiled for 5 min to terminate proteolytic activity,
dried, and desalted. The extent of degradation was quantified after cationic-PAGE, using
Image Lab relative quantity tool. Subsequently, the degradation of HTN3-loaded CNs in
WSS was assessed by mixing 0.5 mL of the HTN3-loaded CNs (containing 50 µg of HTN3)
with diluted WSS (100 µg salivary protein/mL) to reach a final volume of 1 mL. The final
pH was standardized to 6.8 with 1 M HCl or 1 M NaOH, depending on the initial pH of
saliva. An aliquot of 100 µL was collected after incubation at 37 ◦ C at the following time
points: 0, 0.5, 1, 2, 3, and 6 h. The pH was adjusted to 3 to release all of the HTN3 within
the delivery system. After centrifugation with a 10 kDa Nanosep filter, the filtrate was
retrieved and boiled for 5 min to terminate proteolytic activity. Samples were dried and
desalted, followed by cationic-PAGE. The extent of degradation was quantified by Image
Lab through the relative quantity tool.
2.6. Streptococcus mutans Killing Assay and Biofilm Formation
S. mutans (UA 159) colonies were spiked from blood agar and grown for 14 h in
10 mL of tryptone yeast extract broth (TYEB) supplemented with 1% glucose at 37 ◦ C and
10% CO2 . After incubation, the bacterial suspension was washed twice with 0.9% NaCl
and the pellet was resuspended in 1.2 mL of phosphate-buffered saline (PBS). The optical
density (OD) at 600 nm was adjusted to 1.5, corresponding to a bacterial concentration
of 1 × 109 CFU/mL, based on a growth curve previously done. An aliquot of 0.1 mL
of the bacterial suspension with 1.5 OD reading was added to 9.9 mL of PBS to obtain
a bacterial concentration of 107 CFU/mL. This suspension was then added to an equal
volume of a serial dilution series of HTN3 from 0 to 200 µM in a 96-well polypropylene
microtiter plate. The samples were then incubated at 37 ◦ C for 1.5 h. After incubation, each
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sample was diluted 103 and 104 -fold in PBS, and 20 µL of each dilution was plated onto
Todd Hewitt broth (THB) agar plates. Bacterial viability was assessed by colony counting
using comparisons against control samples incubated without HTN3. The IC50 value was
calculated based on the dose–response curve and used in the biofilm study described below.
To assess the capability of HTN3-loaded CNs to reduce S. mutans biofilm formation on
hydroxyapatite (HA) discs, the discs were fixated on the interior of a 24-well polypropylene
microtiter plate lid, where the discs were carefully positioned so that the plate lid fits both
24 and 96-well plates. The plate lid was placed to immerse all discs in a 96-well plate filled
with 200 µL of 5 different treatment solutions (n = 6/group): control (PBS), 7.4 µM HTN3,
0.1% w/v unloaded CNs, 0.1% w/v CNs containing 7.4 µM of encapsulated HTN3, and
12,300 ppm fluoride solution. Treatments were done under constant stirring for 2 h at 37 ◦ C
to allow the formation of a single-component pellicle onto HA, simulating the formation of
the acquired enamel pellicle in the oral cavity. Subsequently, the plate cover was placed
on a 24-well plate with 2 mL of 0.9% w/v NaCl to wash the discs. Afterwards the discs
were immersed into 2 mL of TYEB supplemented with 1% w/v glucose and 107 CFU/mL
of bacteria. The discs were then incubated at 37 ◦ C in 10% CO2 for 8 h. After incubation,
the discs were washed again with NaCl, followed by further incubation for 16 h immersed
in 2 mL of TYEB supplemented with 0.1 mM glucose. Over the next 4 days, the discs
were incubated in a repeating cycle between solution 1 and 2 where solution 1 was TYEB
supplemented with 1% w/v sucrose for 8 h, and solution 2 was TYEB supplemented with
0.1 mM glucose for 16 h. On the 6th day, all discs were transferred to separate tubes
filled with 1 mL of PBS, followed by sonication to remove the biofilms off the discs. An
aliquot of 0.5 mL of the suspension was transferred to preweighted tubes and centrifuged
at 14,000× g for 5 min. The supernatant was removed, and the biofilm wet weight was
measured. The same suspension was diluted 106 and 107 times in PBS, and 20 µL of each
dilution was plated onto THB agar plates, incubated for 48 h at 37 ◦ C and 10% CO2 , and
then bacterial viability was assessed by colony counting.
2.7. Statistical Analyses
Statistical analyses were performed using software Prism 8.0 GraphPad. Biofilm mass
and bacterial viability were analyzed by ordinary one-way ANOVA followed by Tukey’s
multiple comparisons test between each treatment group. The level of significance (α) was
set at 0.05 (95% confidence interval).
3. Results
3.1. Results
3.1.1. Optimization of CNs Formulation
Four different types of chitosan were investigated to select the best formulation. As
shown in Figure 1a, in general the particles were unstable and aggregated at low chitosan to
TPP mass ratios. At higher ratios, stable particles were formed and the diameter decreased.
Upon further increasing the chitosan to TPP mass ratio, the particle diameter steadily
increased for most systems. PDI followed a similar trend as demonstrated in Figure 1b.
Zeta potential increased steadily with a corresponding increase in chitosan to TPP ratio.
Based on these results, CNs prepared from ultra low MW chitosan were selected as the
optimal formulation, because they had the smallest particle diameter (Figure S1), lowest
PDI, with a fairly high zeta potential. The particle diameter, PDI, and zeta potential were
stable at 4 ◦ C for at least 60 days (Figure S2).
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To assess the protection offered through encapsulation against enzymatic degradation in the oral cavity, a protein degradation study was conducted in diluted human saliva
to compare the degradation kinetics of free HTN3 and HTN3 loaded CNs. The degradation over time was quantified for both free HTN3 and HTN3 loaded CNs (Figure 5 and
of 15
Table S1). For free HTN3, only 6% ± 5% of the free HTN3 remained after 2 h, whereas947%
± 8% of HTN3 was intact when it was encapsulated in the CNs delivery system.
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Bacterial cell viability was also evaluated and presented in Figure 7. The PBS control
led to 5.0 × 109 ± 0.4 × 108 CFU/mL of viable bacteria, while free HTN3 had 4.6 × 109 ± 0.3 ×
109 CFU/mL, fluoride had 3.8 × 109 ± 0.5 × 109 CFU/mL, unloaded CNs had 2.7 × 109 ± 0.4 ×
109 CFU/mL, and HTN3-loaded CNs had 2.3 × 109 ± 0.3 × 109 CFU/mL.
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perhaps be attributed to more chitosan per particle or aggregation of the particles. For the
same reasons, the PDI also followed a similar trend. For the zeta potential, a steady increase was observed with increasing chitosan to TPP ratios, since chitosan is positively
charged. The findings are in agreement with many studies in the literature [42,43].
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can perhaps be attributed to more chitosan per particle or aggregation of the particles. For
the same reasons, the PDI also followed a similar trend. For the zeta potential, a steady
increase was observed with increasing chitosan to TPP ratios, since chitosan is positively
charged. The findings are in agreement with many studies in the literature [42,43].
The optimal formulation was selected based on particle diameter, PDI, and zeta
potential. Ideally, it is best to have a formulation with a sub-200 nm diameter nanoparticles,
with a relatively low PDI and a high zeta potential. Therefore, the ultra-low MW chitosan
formulation at a ratio of 6.94:1 (chitosan to TPP) was chosen as it has the smallest particle
diameter of 144 ± 6 nm, with the lowest PDI of 0.15 ± 0.04 and a zeta potential of 18 ± 4 mV.
Through a colloidal stability study by time-course of particle size and PDI measurements
by DLS, we found that these nanoparticles maintain their average diameter and PDI when
the zeta potential is above 15 mV. These optimized CNs were visualized by TEM and the
average particle diameter estimated from the TEM images was in good agreement with the
average particle diameter obtained from DLS. Since HTN3 is a low MW salivary protein,
its encapsulation in the CNs did not significantly affect the particle diameter. As shown
by the TEM images, there were no significant differences in size or dispersity between the
unloaded CNs and those with different HTN3 loading ratios.
The pH-responsive properties of the optimized CNs were also investigated. The
extent of swelling under different pH conditions was studied. The highest degree of
swelling was observed at pH 3 and the CNs remained unchanged at pH 6.3. The results
also demonstrated that the degree of swelling depended on the acidity of the suspension.
The swelling response elicited by the pH stimulus was rapid, suggesting that CNs were
able to quickly respond to pH changes. The versatility of this pH-responsive property was
further examined through pH-cycling between 6.3 and 4, and the results suggested the
CNs delivery system was capable of swelling selectively at acidic pH and reversed the
swelling process upon removal of the pH stimulus.
The encapsulation loading efficiency of HTN3 was studied at 2%, 5%, and 10% w/w
loading ratios of HTN3 to chitosan. The absence of unloaded protein suggested that HTN3
was quantitatively encapsulated in the delivery system at all ratios, which is beneficial,
as the loading can therefore be tuned. Cumulative release studies at different pH values
including 3, 4, 5, and 6.8 were also conducted to assess the extent of release of encapsulated HTN3 from the delivery system. These values were chosen because they reflect the
cariogenic conditions promoting different oral diseases. For instance, dental caries initiate
at pH 5 and dental erosion occurs at pH 3. In accordance with the demonstration of the
pH-responsive property shown previously, the extent of HTN3 release was proportionate to
the acidity of the environment. A maximum cumulative release of 84% ± 7% was achieved
at pH 3 over 210 min, while a minimum release of 2% ± 2% was observed at pH 6.8 over
the same time period. To better mimic the pH changes in the oral cavity throughout the
day, pH-cycling release was performed between pH 6.8 and 4. HTN3-loaded CNs were
able to selectively release encapsulated HTN3 at pH 4, and retain the HTN3 at the salivary
pH of 6.8. The ability to selectively release HTN3 under acidic conditions is crucial because
throughout the day the salivary pH fluctuates many times from the consumption of food
or beverages [23,44]. As saliva becomes acidic following carbohydrate intake, the drop in
pH could trigger the release of HTN3, which promotes oral homeostasis by inhibiting the
demineralization process. Salivary pH would gradually recover to its physiological value
due to the buffer capacity of saliva, which would halt HTN3 release from the CNs. Further
release of HTN3 would require another sugar challenge, which would drop salivary pH.
Salivary proteins are susceptible to the high proteolytic activity in the oral cavity,
which prevent them from being used as potential therapeutics on their own. To evaluate
the protection offered through CN encapsulation against enzymatic degradation, a protein
degradation study was performed in 10-fold diluted human saliva. Saliva was diluted
to better capture the degradation kinetics of proteins, since at the original concentration
the degradation would have happened too rapidly to allow easy measurement of the
process. Only 6% ± 5% of the free HTN3 remained at the 2-h mark. At the same time
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point, 47% ± 8% of HTN3 was still present in the CN delivery system. At the 6-h mark,
only 7% ± 1% of HTN3 remained in the delivery system, which could be due to the
potential breakdown of the CNs by other salivary proteins. Nevertheless, the delivery
system increased the protein survival time significantly. The increase in survival time is
important because it allows less frequent administration of the formulation.
Ultimately, a biofilm model was applied to evaluate the therapeutic effect of HTN3loaded CNs against S. mutans biofilm formation on hydroxyapatite discs. S. mutans was
chosen because it is a major contributor responsible for the initiation and development
of tooth decay [23,45]. It metabolizes sucrose to produce sticky polysaccharides that
allow the bacteria to aggregate and adhere to the tooth enamel, forming a biofilm. The
biofilm, together with frequent sugar intake promotes fermentation of dietary sugar into
acidic products. Persistence of the resulting acidic conditions favours the proliferation
of acidogenic bacteria. The low pH environment in the biofilm initiates the dental caries
process [23,46]. Hydroxyapatite is a mineral composed of calcium phosphate, which
greatly resembles human hard tissues including bone and tooth enamel in composition and
morphology [47]. It is also the most stable calcium phosphate mineral under physiological
conditions [48]. Therefore it has been extensively used in oral applications, such as pellicle
formation and biofilm formation [49,50].
Two key factors used to evaluate biofilm growth are biofilm mass and bacterial cell
viability. Effective treatment should result in low biofilm mass and reduced bacterial cell
viability. For biofilm mass measurements, based on the ANOVA analysis and Tukey’s
multiple comparisons test, all four treatment groups resulted in significantly reduced
biofilm mass compared to the control group. Fluoride together with unloaded and HTN3loaded CNs were significantly more effective than free HTN3. However, no significant
difference was observed between the HTN3-loaded CNs and unloaded CNs. Both of
these treatments successfully lowered the biofilm mass by at least half. Bacterial cell
viability was also determined for all treatment groups. Free HTN3 was not effective at
reducing bacterial cell viability and did not perform better than the control group. Fluoride,
unloaded, and HTN3-loaded CNs significantly reduced cell viability when compared
against the control group. Fluoride was significantly more effective when compared
against HTN3. Unloaded and HTN3-loaded CNs were the most competent treatment
groups. They reduced cell viability in half, but their performance in reducing bacterial
population were not significantly different from one another. While these results suggest
that CNs alone can potentially control bacterial population growth, further studies that
encapsulate greater HTN3 concentrations within CNs, or reduce the amount of CNs while
maintaining HTN3 concentrations are required. In addition, CNs are known to exhibit
antimicrobial effects against S. mutans [51]. Another possible explanation would be CNs
alone already prevented the initiation of demineralization, therefore there was no steep
drop in pH to trigger HTN3 release from the CNs.
5. Conclusions
In conclusion, the results of this study demonstrated the pH-responsive properties
of the CNs. The CNs were also able to offer protection against enzymatic degradation
in comparison to free HTN3. While HTN3-loaded CNs had successfully reduced biofilm
growth as reflected by reduced biofilm mass and bacterial cell viability, these particles
did not significantly outperform unloaded CNs. Future studies should include use of
the biofilm model to characterize the contribution of HTN3 within CNs and CNs alone
in controlling bacterial population. Nonetheless, this work has shown that CNs can be
used as a protein carrier for oral applications, especially for complications involving acidic
environments. This delivery system can also be applied to encapsulate other salivary
proteins for oral delivery. The ultimate goal of studying protein encapsulation within CNs
is to integrate multifunctional salivary proteins into daily dental hygiene products like
toothpaste and mouthwash to provide a preventative approach to address dental caries.
Altogether, our results show that a pH-sensitive delivery system that can release salivary
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proteins under oral conditions can be achieved by utilizing a biodegradable, biocompatible,
and naturally derived polymer like chitosan.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/nano11041028/s1, Figure S1: Volume distribution of the ultra-low MW CNs at chitosan to
TPP mass ratio of 6.94. There is a small batch to batch variability; Figure S2: CNs were stored at
4 ◦ C, and three parameters including (a) Z-average diameter, (b) PDI, and (c) Zeta potential were
measured by DLS routinely over the course of 60 days. The consistency of obtained data suggest
the nanoparticles are stable; Figure S3: TEM images of (a) blank chitosan nanoparticles, (b) HTN3
loaded chitosan nanoparticles with a 2% w/w loading ratio, (c) HTN3 loaded chitosan nanoparticles
with a 5% w/w loading ratio, and (d) HTN3 loaded chitosan nanoparticles with a 10% w/w loading
ratio. No significant variance in size or dispersity was observed among blank chitosan nanoparticles
and those with different loading ratios; Table S1: Protein degradation over time for free HTN3 and
HTN3-loaded into CNs.
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